BioSpace News Archive

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024.

Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon Medical” or the “Company”), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the first quarter ended March 31, 2024.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced its financial results for the three months and six months ended March 31, 2024 and provided a business update.

Metagenomi, Inc. reported financial results and business updates for the first quarter ended March 31, 2024.

Serina Therapeutics, a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, reported financial results for the quarter ended March 31, 2024 and provided business highlights.

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) today reported financial results and operating highlights for the first quarter ended March 31, 2024.

Ardelyx, Inc. announced that on May 6, 2024, the compensation committee of the company’s board of directors granted 26 new non-executive employees options to purchase an aggregate of 511,500 shares of the company’s common stock, and granted 32 new non-executive employees an aggregate of 425,050 Restricted Stock Units.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2024, and provided a business update.

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the first quarter 2024 and provided a corporate update.

BioStem Technologies Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, reported financial results for the first quarter ended March 31, 2024.